AlphAIAlphAI — Financial news for AI agents
Zacks CommentaryNOV 133 min read$DARE

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 13, 2025, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2025, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates — source image
Source · www.zacks.com
Decision brief

The 30-second read

$DARENeutralLow
01

Why it matters

The mixed results suggest cautious market sentiment; revenue decline raises concerns about growth sustainability, but earnings surprise indicates some operational efficiency.

02

Market read

Limited immediate impact on broader markets; sector-specific caution advised.

03

What to watch

Potential upcoming catalysts such as new product launches or partnerships that could alter the outlook.

Timing: short-term; immediate reaction expected within days.

Background

Dare Bioscience reported Q3 2025 earnings with a 15.15% positive earnings surprise but a 95% revenue decline, indicating operational challenges amid a competitive biotech landscape.

Company-level read

Ticker impact

$DARENeutralMedium confidence
Context

Primary focus due to recent earnings report.

Expected impact

Potential short-term stagnation or slight decline; long-term outlook remains uncertain pending strategic adjustments.

Evidence & confidence

Mixed earnings results with a notable revenue decline suggest limited upside in the near term, but positive earnings surprise indicates some operational resilience.

Market effects

Sector

Potential cautious sentiment in biotech and life sciences sectors due to earnings volatility.

Regional

Limited; company-specific news unlikely to influence broader regional markets.

Global

Low; Dare Bioscience's size and market presence suggest minimal global market impact.

Counterpoint

What could challenge this read

The revenue decline may be a temporary setback; if the company implements effective strategic changes, the stock could rebound.

Key entities

  • Company
    Dare Bioscience, Inc.

    A biotechnology company focused on women's health and reproductive health products.

Read at source← All news

Related articles

SEP 14
$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.

rttnews.com2 min
AUG 13
$DAREMed

Dare Bioscience, Inc. (DARE): Results of Operations and Financial Condition

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to

SEC EDGAR 8-K7 min
SEP 27
$NVOMedAI 8/10

Novo Nordisk Searches for Growth Beyond its Biggest Franchise

Novo Nordisk (NYSE: NVO) plans to diversify beyond obesity and diabetes, aiming for over DKK 150 billion in pipeline sales by 2035. The company faces competition and pricing pressure, with obesity and diabetes accounting for 90% of 2025 sales. Novo is expanding its portfolio and may pursue acquisitions, but risks include high costs and execution challenges.

insidermonkey.com2 min
SEP 27
$NKEMed

Nike Bank of America downgrade 2026

Bank of America downgraded Nike to Underperform, cutting its price target to $30 from $47. Analyst Lorraine Hutchinson delayed sales recovery expectations to fiscal 2028, reducing EPS estimates. China revenue fell 17% in Q4, and wholesale partners face inventory issues. Nike shares have dropped over 40% since January, nearing 52-week lows.

sgieurope.com2 min